title: [An effective case of liver metastasis of breast cancer treated with capecitabine + docetaxel combination therapy using vitamin B6].
abstract: Capecitabine + docetaxel combination therapy proves highly effective against the advanced or recurrent breast cancer. Therefore, it has been investigated as a first-line treatment for metastatic breast cancer. Hand-foot syndrome (HFS), a typical side effect of capecitabine, decreases the QOL of patients and sometimes prevents further medication using capecitabine. A 56-year-old woman who had liver, bone and local skin metastases two years after her left breast cancer operation, was treated with capecitabine + docetaxel combination therapy. Severe HFS disturbed the continuation of the therapy. Some other chemo-therapies were attempted after discontinuing the therapy; however, the metastases progressed. Finally, we tried to prevent HFS with vitamin B6 and started the capecitabine + docetaxel combination therapy. HFS was controlled completely. The liver tumor disappeared in MRI and CT images after 18 courses. In this case, vitamin B6 seemed to be effective to control HSF and allow continuation of capecitabine + docetaxel combination therapy.
authors.affiliation: Department of General Surgery, Shiga University of Medical Science.
authors.forename: Tomoko
authors.initials: T
authors.lastname: Umeda
authors.forename: Hajime
authors.initials: H
authors.lastname: Abe
authors.forename: Hirotomi
authors.initials: H
authors.lastname: Cho
authors.forename: Tomoharu
authors.initials: T
authors.lastname: Shimizu
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Mori
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Kubota
authors.forename: Yuki
authors.initials: Y
authors.lastname: Kawai
authors.forename: Makiko
authors.initials: M
authors.lastname: Tanaka
authors.forename: Yoshimasa
authors.initials: Y
authors.lastname: Kurumi
authors.forename: Tohru
authors.initials: T
authors.lastname: Tani
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D000069287:Capecitabine; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077143:Docetaxel; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D012878:Skin Neoplasms / Q000188:drug therapy / Q000556:secondary; D043823:Taxoids / Q000008:administration & dosage / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed; D025101:Vitamin B 6 / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D043823:Taxoids; D003841:Deoxycytidine; D000077143:Docetaxel; D000069287:Capecitabine; D025101:Vitamin B 6; D005472:Fluorouracil